Daniel T. Chiu
Directeur/Membre du Conseil chez FLUICELL AB
Profil
Daniel T.
Chiu is the founder of Cellectricon AB, founded in 2000, and MiCareo, Inc., founded in 2011.
He is currently an Independent Director at Fluicell AB since 2017 and a Professor at the University of Washington since 2006.
Dr. Chiu holds a doctorate degree from Harvard University and an undergraduate degree from Stanford University.
Postes actifs de Daniel T. Chiu
| Sociétés | Poste | Début |
|---|---|---|
| FLUICELL AB | Directeur/Membre du Conseil | 01/01/2017 |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | 29/10/2009 |
MiCareo, Inc.
 MiCareo, Inc. BiotechnologyHealth Technology MiCareo, Inc. provides tools for the analysis of rare cells. It circulates tumor cell platform does rare cell isolation and analysis for cancer prognosis, treatment development, and efficacy evaluation. The firm’s product MiSelect starts with whole blood labeled with any fluorescent cell surface antibody or cocktail of multiple antibodies. The company was founded by Perry Schiro and Daniel T. Chiu in 2011 and is headquartered in Taipei, Taiwan. | Fondateur | 01/01/2011 |
Anciens postes connus de Daniel T. Chiu
| Sociétés | Poste | Fin |
|---|---|---|
Cellectricon AB
 Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Fondateur | - |
Formation de Daniel T. Chiu
| Stanford University | Undergraduate Degree |
| Harvard University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FLUICELL AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cellectricon AB
Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Commercial Services |
MiCareo, Inc.
MiCareo, Inc. BiotechnologyHealth Technology MiCareo, Inc. provides tools for the analysis of rare cells. It circulates tumor cell platform does rare cell isolation and analysis for cancer prognosis, treatment development, and efficacy evaluation. The firm’s product MiSelect starts with whole blood labeled with any fluorescent cell surface antibody or cocktail of multiple antibodies. The company was founded by Perry Schiro and Daniel T. Chiu in 2011 and is headquartered in Taipei, Taiwan. | Health Technology |
